Literature DB >> 25488749

Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.

Guangwu Guo1, Juliann Chmielecki1, Chandra Goparaju2, Adriana Heguy3, Igor Dolgalev3, Michele Carbone4, Sara Seepo5, Matthew Meyerson6, Harvey I Pass7.   

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive neoplasm associated with asbestos exposure. Although previous studies based on candidate gene approaches have identified important common somatic mutations in MPM, these studies have focused on small sets of genes and have provided a limited view of the genetic alterations underlying this disease. Here, we performed whole-exome sequencing on DNA from 22 MPMs and matched blood samples, and identified 517 somatic mutations across 490 mutated genes. Integrative analysis of mutations and somatic copy-number alterations revealed frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1. Our study presents the first unbiased view of the genomic basis of MPM. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25488749     DOI: 10.1158/0008-5472.CAN-14-1008

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  109 in total

1.  Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.

Authors:  Yoshiaki Kinoshita; Makoto Hamasaki; Masayo Yoshimura; Shinji Matsumoto; Akinori Iwasaki; Kazuki Nabeshima
Journal:  Mod Pathol       Date:  2019-06-23       Impact factor: 7.842

2.  MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.

Authors:  Anand Singh; Nisan Bhattacharyya; Abhishek Srivastava; Nathanael Pruett; R Taylor Ripley; David S Schrump; Chuong D Hoang
Journal:  Mol Ther       Date:  2019-06-04       Impact factor: 11.454

Review 3.  The Cappadocia mesothelioma epidemic: its influence in Turkey and abroad.

Authors:  Salih A Emri
Journal:  Ann Transl Med       Date:  2017-06

4.  Recent insights emerging from malignant mesothelioma genome sequencing.

Authors:  Michele Carbone; Giovanni Gaudino; Haining Yang
Journal:  J Thorac Oncol       Date:  2015-03       Impact factor: 15.609

5.  Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma.

Authors:  Navid Sobhani; Silvia P Corona; Fabrizio Zanconati; Daniele Generali
Journal:  Genes Cancer       Date:  2017-03

6.  Personalized treatment of malignant mesothelioma-dream or reality?

Authors:  Anja C Roden
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

7.  Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.

Authors:  Chiara Riganti; Marcello Francesco Lingua; Iris Chiara Salaroglio; Chiara Falcomatà; Luisella Righi; Deborah Morena; Francesca Picca; Daniele Oddo; Joanna Kopecka; Monica Pradotto; Roberta Libener; Sara Orecchia; Paolo Bironzo; Valentina Comunanza; Federico Bussolino; Silvia Novello; Giorgio Vittorio Scagliotti; Federica Di Nicolantonio; Riccardo Taulli
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

8.  Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.

Authors:  Eleonora Sementino; Craig W Menges; Yuwaraj Kadariya; Suraj Peri; Jinfei Xu; Zemin Liu; Richard G Wilkes; Kathy Q Cai; Frank J Rauscher; Andres J Klein-Szanto; Joseph R Testa
Journal:  J Cell Physiol       Date:  2018-06-15       Impact factor: 6.384

Review 9.  Current chemotherapy strategies in malignant pleural mesothelioma.

Authors:  Cornedine Jannette de Gooijer; Paul Baas; Jacobus Adrianus Burgers
Journal:  Transl Lung Cancer Res       Date:  2018-10

10.  The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.

Authors:  Aatur D Singhi; Alyssa M Krasinskas; Haroon A Choudry; David L Bartlett; James F Pingpank; Herbert J Zeh; Alyssa Luvison; Kimberly Fuhrer; Nathan Bahary; Raja R Seethala; Sanja Dacic
Journal:  Mod Pathol       Date:  2015-10-23       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.